Matches in SemOpenAlex for { <https://semopenalex.org/work/W2913204060> ?p ?o ?g. }
Showing items 1 to 66 of
66
with 100 items per page.
- W2913204060 abstract "619 Background: Regorafenib (at a starting dose of 160 mg/day, rego 160), regorafenib (with a weekly dose escalation, rego 80+) and TAS-102, are suggested treatment options for refractory metastatic colorectal cancer (mCRC). We aimed to evaluate the comparative effectiveness evidence supporting these 3 strategies. Methods: We searched PubMed, Embase, and Cochrane CENTRAL, for randomized controlled trials evaluating TAS 102 or regorafenib in refractory mCRC patients who progressed on/intolerant of previous oxaliplatin, irinotecan, and fluoropyrimidine. Outcomes of interest included OS and PFS. The overall effect was pooled using the DerSimonian random effects model. We conducted network meta-analysis based on White’s multivariate meta-regression to pool evidence from direct and indirect comparisons. Results: Six trials (3 of regorafenib and 3 of TAS-102) at low risk of bias (2,445 patients) were included. Direct comparisons showed that Rego 160 and TAS-102 as monotherapy were superior to BSC in terms of PFS (Rego 160: HR = 0.4, CI 0.26 to 0.63; TAS-102: HR = 0.46, CI 0.40 to 0.52) and OS (Rego 160: HR = 0.67, CI 0.48 to 0.93; TAS-102: HR = 0.67, CI 0.57 to 0.80). Network analysis showed that there was no difference in PFS or OS between Rego 160 and TAS-102. Rego 80+ was superior to BSC in terms of OS (HR = 0.44, CI 0.23 to 0.84) and PFS (HR = 0.37, CI 0.21 to 0.66). There was a numerical advantage for Rego 80+ compared to TAS-102 and Rego 160 (see table). Conclusions: Regorafenib 160 and TAS-102 appear to have similar efficacy. Rego 80+ is shown to be superior to BSC. A trend for improved OS was observed with Rego 80+ versus Rego 160 or TAS 102. [Table: see text]" @default.
- W2913204060 created "2019-02-21" @default.
- W2913204060 creator A5018405630 @default.
- W2913204060 creator A5028159293 @default.
- W2913204060 creator A5035100026 @default.
- W2913204060 creator A5054802858 @default.
- W2913204060 creator A5059366804 @default.
- W2913204060 creator A5062280376 @default.
- W2913204060 creator A5064791048 @default.
- W2913204060 creator A5065058975 @default.
- W2913204060 creator A5074891676 @default.
- W2913204060 creator A5077416215 @default.
- W2913204060 date "2019-02-01" @default.
- W2913204060 modified "2023-09-27" @default.
- W2913204060 title "A systematic review and network meta-analysis of regorafenib and TAS-102 in refractory metastatic colorectal cancer." @default.
- W2913204060 doi "https://doi.org/10.1200/jco.2019.37.4_suppl.619" @default.
- W2913204060 hasPublicationYear "2019" @default.
- W2913204060 type Work @default.
- W2913204060 sameAs 2913204060 @default.
- W2913204060 citedByCount "0" @default.
- W2913204060 crossrefType "journal-article" @default.
- W2913204060 hasAuthorship W2913204060A5018405630 @default.
- W2913204060 hasAuthorship W2913204060A5028159293 @default.
- W2913204060 hasAuthorship W2913204060A5035100026 @default.
- W2913204060 hasAuthorship W2913204060A5054802858 @default.
- W2913204060 hasAuthorship W2913204060A5059366804 @default.
- W2913204060 hasAuthorship W2913204060A5062280376 @default.
- W2913204060 hasAuthorship W2913204060A5064791048 @default.
- W2913204060 hasAuthorship W2913204060A5065058975 @default.
- W2913204060 hasAuthorship W2913204060A5074891676 @default.
- W2913204060 hasAuthorship W2913204060A5077416215 @default.
- W2913204060 hasConcept C121608353 @default.
- W2913204060 hasConcept C126322002 @default.
- W2913204060 hasConcept C143998085 @default.
- W2913204060 hasConcept C2776248978 @default.
- W2913204060 hasConcept C2780259306 @default.
- W2913204060 hasConcept C2780962732 @default.
- W2913204060 hasConcept C526805850 @default.
- W2913204060 hasConcept C71924100 @default.
- W2913204060 hasConcept C95190672 @default.
- W2913204060 hasConceptScore W2913204060C121608353 @default.
- W2913204060 hasConceptScore W2913204060C126322002 @default.
- W2913204060 hasConceptScore W2913204060C143998085 @default.
- W2913204060 hasConceptScore W2913204060C2776248978 @default.
- W2913204060 hasConceptScore W2913204060C2780259306 @default.
- W2913204060 hasConceptScore W2913204060C2780962732 @default.
- W2913204060 hasConceptScore W2913204060C526805850 @default.
- W2913204060 hasConceptScore W2913204060C71924100 @default.
- W2913204060 hasConceptScore W2913204060C95190672 @default.
- W2913204060 hasLocation W29132040601 @default.
- W2913204060 hasOpenAccess W2913204060 @default.
- W2913204060 hasPrimaryLocation W29132040601 @default.
- W2913204060 hasRelatedWork W2075405356 @default.
- W2913204060 hasRelatedWork W2320881404 @default.
- W2913204060 hasRelatedWork W2740375361 @default.
- W2913204060 hasRelatedWork W2888515079 @default.
- W2913204060 hasRelatedWork W2907419770 @default.
- W2913204060 hasRelatedWork W2954373381 @default.
- W2913204060 hasRelatedWork W2969718979 @default.
- W2913204060 hasRelatedWork W3040695971 @default.
- W2913204060 hasRelatedWork W3203415798 @default.
- W2913204060 hasRelatedWork W4283788271 @default.
- W2913204060 isParatext "false" @default.
- W2913204060 isRetracted "false" @default.
- W2913204060 magId "2913204060" @default.
- W2913204060 workType "article" @default.